Revakinagene taroretcel

Last updated

Revakinagene taroretcel
Clinical data
Trade names Encelto
Other namesNTC-201-6A, revakinagene taroretcel-lwey
License data
Routes of
administration 		Intravitreal implantation
ATC code
  • None
Legal status
Legal status
Identifiers
UNII

Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2. [1] [2] Revakinagene taroretcel is administered into the recipient's eye during a single surgical procedure. [3]

Contents

Revakinagene taroretcel works by expressing recombinant human ciliary neurotrophic factor, which is a factor that may promote the survival and maintenance of the macular photoreceptors. [3]

Revakinagene taroretcel was approved for medical use in the United States in March 2025. [3] [4]

Medical uses

Revakinagene taroretcel is indicated for the treatment of adults with idiopathic macular telangiectasia type 2. [1] [4]

Macular telangiectasia type 2 is a rare progressive disease of the macula (portion of the eye that process sharp central vision), leading to degeneration of the photoreceptors which are specialized light-detecting cells in the back of the eye. [3]

Society and culture

Revakinagene taroretcel was approved for medical use in the United States in March 2025. [4] [5]

Names

Revakinagene taroretcel is the international nonproprietary name [6] and the United States Adopted Name. [7]

References

  1. 1 2 3 "ENCELTO (revakinagene taroretcel-lwey) implant, for intravitreal use". Neurotech Pharmaceuticals, Inc. U.S. Food and Drug Administration. 2025.
  2. ↑ Rim MH, Dean C, Aliaj E, Karas BL, Barada F, Levitsky AM (November 2024). "Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)". American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. 81 (22): 1103–1108. doi:10.1093/ajhp/zxae242. PMID   39194065.
  3. 1 2 3 4 "FDA Roundup: March 7, 2025". U.S. Food and Drug Administration. 7 March 2025. Retrieved 7 March 2025.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  4. 1 2 3 "Encelto". U.S. Food and Drug Administration. 1 October 2024. Retrieved 7 March 2025.
  5. ↑ "Neurotech's Encelto (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)" (Press release). Neurotech. 6 March 2025. Retrieved 7 March 2025– via Business Wire.
  6. ↑ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl: 10665/340684 .
  7. ↑ "Revakinagene taroretcel". AMA Finder. Retrieved 7 March 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.